Mammalian target of rapamycin as a target in hematological malignancies

被引：15
作者：
Kelly, Kevin R. [1 ]
Rowe, Julie H. [1 ]
Padmanabhan, Swaminathan [1 ]
Nawrocki, Steffan T. [1 ]
Carew, Jennifer S. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
TARGETED ONCOLOGY | 2011年 / 6卷 / 01期
关键词：
mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;
D O I：
10.1007/s11523-011-0175-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
引用
收藏
页码：53 / 61
页数：9
相关论文
共 50 条
  • [31] Mammalian target of rapamycin and tuberous sclerosis complex
    Wataya-Kaneda, Mari
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2015, 79 (02) : 93 - 100
  • [32] Mammalian Target of Rapamycin (mTOR) Signaling Network in Skeletal Myogenesis
    Ge, Yejing
    Chen, Jie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (52) : 43928 - 43935
  • [33] New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma
    Agulnik, Mark
    CANCER, 2012, 118 (06) : 1486 - 1497
  • [34] The JAK-STAT pathway: A therapeutic target in hematological malignancies
    Ferrajoli, A.
    Faderl, S.
    Ravandi, F.
    Estrov, Z.
    CURRENT CANCER DRUG TARGETS, 2006, 6 (08) : 671 - 679
  • [35] Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer
    Nelson, Valerie
    Altman, Jessica K.
    Platanias, Leonidas C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 715 - 722
  • [36] Mammalian Target of Rapamycin (mTOR) Inhibitors Potential Uses and a Review of Haematological Adverse Effects
    Sofroniadou, Sofia
    Goldsmith, David
    DRUG SAFETY, 2011, 34 (02) : 97 - 115
  • [37] Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo
    Xie, Hua
    Zhu, Feng
    Huang, Zunnan
    Lee, Mee-Hyun
    Kim, Dong Joon
    Li, Xiang
    Lim, Do Young
    Jung, Sung Keun
    Kang, Soouk
    Li, Haitao
    Reddy, Kanamata
    Wang, Lei
    Ma, Weiya
    Lubet, Ronald A.
    Bode, Ann M.
    Dong, Zigang
    CARCINOGENESIS, 2012, 33 (09) : 1814 - 1821
  • [38] Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma
    Reis, Henning
    Hager, Thomas
    Wohlschlaeger, Jeremias
    Bauer, Sebastian
    Katenkamp, Kathrin
    Katenkamp, Detlef
    Baba, Hideo-Andreas
    HUMAN PATHOLOGY, 2013, 44 (10) : 2266 - 2274
  • [39] Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
    De Veirman, Kim
    Van Valckenborgh, Els
    Lahmar, Qods
    Geeraerts, Xenia
    De Bruyne, Elke
    Menu, Eline
    Van Riet, Ivan
    Vanderkerken, Karin
    Van Ginderachter, Jo A.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [40] Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis
    Yagyu, T.
    Tsuji, Y.
    Haruta, S.
    Kitanaka, T.
    Yamada, Y.
    Kawaguchi, R.
    Kanayama, S.
    Tanase, Y.
    Kurita, N.
    Kobayashi, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (04) : 1545 - 1551
12345